HNSCC ID-3 Translational therapy monitoring of locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) with 18F-FDG PET-CT and liquid biopsy under immunotherapy

HNSCC ID-3 Translational therapy monitoring of locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) with 18F-FDG PET-CT and liquid biopsy under immunotherapy - HNSCC ID

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025330

Enrollment

Registered

2021-08-31

Start date

2021-11-30

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C12 C13 C14 C30 C31 C32

Interventions

Group 1: Patients with HNSCC will be examined at three time points of response assessment - at baseline, 8-12 weeks later, 6 months later - with 18F-FDG PET/CT and liquid biopsy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - First-line immunotherapy - locally advanced / metastatic disease - target lesions in PET/CT - life expectancy > 6 months

Exclusion criteria

Exclusion criteria: - autoimmune disease - local resection or treatment of HNSCC - treatment with steroids or immunosuppressive medication

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	—

Secondary

Measure	Time frame
Overall Survival	—

Countries

Germany

Contacts

Public ContactMaurice Heimer

Klinikum der Universität München Klinik und Poliklinik für Radiologie

maurice.heimer@med.uni-muenchen.de(089) 4400-73620

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026